 SAN DIEGO, June 21, 2021 PRNewswire -- Inhibrx, Inc. Nasdaq: INBX, a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma. INBRX-109 is a precision-engineered, tetravalent death receptor 5 DR5 agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. 